Compare Stocks

→ Move Your Money Before May 1 (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEMD Aethlon Medical	$1.36 -9.5%	$1.65	$1.33 ▼ $5.00	$3.56M	1.88	8,578 shs	19,738 shs
NSPR InspireMD	$2.00 +4.4%	$2.38	$1.03 ▼ $3.85	$46.80M	0.83	33,639 shs	10,220 shs
NVCN Neovasc	$30.03	$29.69	$4.59 ▼ $30.07	$82.28M	1.7	56,993 shs	1 shs

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEMD Aethlon Medical	-1.76%	+6.22%	-14.11%	-16.50%	-61.92%
NSPR InspireMD	+2.16%	-10.85%	-17.83%	-35.71%	+78.13%
NVCN Neovasc	0.00%	0.00%	0.00%	0.00%	0.00%

Move Your Money Before May 1 (Ad)

Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens?

Click here to get the full story before May 1.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEMD Aethlon Medical	1.6401 of 5 stars	3.5	3.0	0.0	0.0	1.9	0.0	0.6
NSPR InspireMD	2.0782 of 5 stars	3.5	0.0	0.0	0.0	1.8	2.5	0.6
NVCN Neovasc	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEMD Aethlon Medical	3.00	Buy	$10.00	635.29% Upside
NSPR InspireMD	3.00	Buy	$4.85	142.50% Upside
NVCN Neovasc	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest NVCN, AEMD, and NSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/4/2024	AEMD Aethlon Medical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $10.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEMD Aethlon Medical	$570K	6.25	N/A	N/A	$6.56 per share	0.21
NSPR InspireMD	$6.20M	7.55	N/A	N/A	$1.83 per share	1.09
NVCN Neovasc	$3.81M	21.60	N/A	N/A	$5.77 per share	5.20

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEMD Aethlon Medical	-$12.03M	-$4.99	N/A	N/A	N/A	N/A	-106.28%	-86.60%	6/26/2024 (Estimated)
NSPR InspireMD	-$19.92M	-$1.08	N/A	N/A	N/A	-320.97%	-55.71%	-46.53%	5/20/2024 (Estimated)
NVCN Neovasc	-$41.20M	-$15.08	N/A	∞	N/A	-1,082.92%	-127.25%	-80.31%	N/A

Latest NVCN, AEMD, and NSPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/6/2024	12/31/2023	NSPR InspireMD	-$0.20	-$0.16	+$0.04	-$0.16	$1.65 million	$1.76 million
2/14/2024	Q3 2024	AEMD Aethlon Medical	-$1.23	-$1.37	-$0.14	-$1.37	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEMD Aethlon Medical	N/A	N/A	N/A	N/A	N/A
NSPR InspireMD	N/A	N/A	N/A	N/A	N/A
NVCN Neovasc	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEMD Aethlon Medical	N/A	3.93	3.93
NSPR InspireMD	N/A	7.34	6.99
NVCN Neovasc	0.80	2.96	2.85

Ownership

Institutional Ownership

Company	Institutional Ownership
AEMD Aethlon Medical	1.99%
NSPR InspireMD	44.78%
NVCN Neovasc	1.64%

Insider Ownership

Company	Insider Ownership
AEMD Aethlon Medical	4.00%
NSPR InspireMD	21.62%
NVCN Neovasc	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AEMD Aethlon Medical	15	2.62 million	2.52 million	Optionable
NSPR InspireMD	65	23.40 million	18.34 million	Optionable
NVCN Neovasc	49	2.74 million	N/A	Not Optionable

NVCN, AEMD, and NSPR Headlines

Source	Headline
	Top Small-Cap Stocks for May 2023 - Investopedia news.google.com - May 13 at 9:38 AM
	FDA accepts application for Roche's Vabysmo for the - GlobeNewswire news.google.com - May 9 at 2:18 AM
	New treatment option opens avenues in geographic atrophy - Healio news.google.com - May 8 at 9:18 PM
	Pachychoroid neovasculopathy has clinical properties that differ ... - Nature.com news.google.com - May 8 at 9:18 PM
	The NOD audit provides data and insights for the management for ... - Modern Retina news.google.com - May 8 at 9:18 PM
	Shockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswire news.google.com - May 8 at 4:17 PM
	Heart valve repair and replacement devices market size to grow by ... - Benzinga news.google.com - May 5 at 9:03 PM
	ASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry Times news.google.com - May 5 at 4:02 PM
	Faricimab in Treatment-Resistant nARMD \| OPTH - Dove Medical Press news.google.com - May 5 at 12:24 AM
	Restoring vision through retinal ganglion cell repopulation - Ophthalmology Times Europe news.google.com - May 5 at 12:24 AM
	STAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD Magazine news.google.com - May 4 at 7:24 PM
	The NOD audit: Insights into the current state of management for ... - Nature.com news.google.com - May 4 at 8:40 AM
	On the horizon: Treatments for both forms of AMD - Ophthalmology Times Europe news.google.com - May 3 at 10:56 AM
	Biosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for Biosimilars news.google.com - April 28 at 3:22 PM
	Real World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets Network news.google.com - April 28 at 10:22 AM
	Low-vision services improve vision, quality of life in patients with ... - Healio news.google.com - April 28 at 10:22 AM
	New Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswire news.google.com - April 25 at 6:55 PM
	New treatment tackles both forms of AMD - Ophthalmology Times news.google.com - April 25 at 6:55 PM
	Price Variation in Economic Evaluations of Infliximab Could ... - The Center for Biosimilars news.google.com - April 25 at 1:32 AM
	1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Finance news.google.com - April 25 at 1:32 AM
	Accel Research expands reach with acquisition of two Florida trial ... - FierceBiotech news.google.com - April 24 at 3:16 PM
	Report: Boston Scientific considering massive deal to acquire ... - Cardiovascular Business news.google.com - April 24 at 3:16 PM
	Boston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics Industry news.google.com - April 21 at 4:24 PM
	The Future of the Structural Heart Disease Intervention Devices ... - Digital Journal news.google.com - April 21 at 10:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aethlon Medical

NASDAQ:AEMD

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.

InspireMD

NYSE:NSPR

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Neovasc

NASDAQ:NVCN

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial